PD-L1 抗体 (Extracellular Domain)
Quick Overview for PD-L1 抗体 (Extracellular Domain) (ABIN1449244)
抗原
See all PD-L1 抗体适用
宿主
克隆类型
标记
应用范围
克隆位点
-
-
抗原表位
- Extracellular Domain
-
特异性
- This antibody reacts with human CD274 antigen.
-
纯化方法
- Protein A agarose
-
免疫原
- Recombinant human PD-L1 extracellular domain
-
亚型
- IgG2b
-
-
-
-
应用备注
- Optimal working dilution should be determined by the investigator.
-
限制
- 仅限研究用
-
-
-
浓度
- 1.0 mg/mL
-
缓冲液
- PBS containing 50 % glycerol, pH 7.2. No preservative is contained.
-
储存液
- Without preservative
-
注意事项
- Avoid repeated freezing and thawing.
-
储存条件
- -20 °C
-
储存方法
- Upon receipt, store (in aliqouts) at -20 °C.
-
-
-
: "Overall survival and PD-L1 expression in metastasized malignant melanoma." in: Cancer, Vol. 117, Issue 10, pp. 2192-201, (2011) (PubMed).
: "Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma." in: Cancer, Vol. 116, Issue 7, pp. 1757-66, (2010) (PubMed).
: "The programmed death (PD)-1/PD-ligand 1 pathway regulates graft-versus-host-reactive CD8 T cells after liver transplantation." in: American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, Vol. 8, Issue 11, pp. 2434-44, (2008) (PubMed).
: "M-CSF: a novel plasmacytoid and conventional dendritic cell poietin." in: Blood, Vol. 111, Issue 1, pp. 150-9, (2008) (PubMed).
: "Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer." in: Proceedings of the National Academy of Sciences of the United States of America, Vol. 104, Issue 9, pp. 3360-5, (2007) (PubMed).
: "Rituximab-induced inhibition of YY1 and Bcl-xL expression in Ramos non-Hodgkin's lymphoma cell line via inhibition of NF-kappa B activity: role of YY1 and Bcl-xL in Fas resistance and ..." in: Journal of immunology (Baltimore, Md. : 1950), Vol. 175, Issue 4, pp. 2174-83, (2005) (PubMed).
-
: "Overall survival and PD-L1 expression in metastasized malignant melanoma." in: Cancer, Vol. 117, Issue 10, pp. 2192-201, (2011) (PubMed).
-
- PD-L1 (CD274 (PD-L1))
-
别名
- CD274 / PDL1
-
背景
- Programmed death ligand 1 (PD-L1, also known as CD274/B7-H1), a member of B7 family was identified by searching for mo lecules that share homology with the immunogloblin V and C domains of B7-1 and B7-2 among the human cDNA expressed sequence tags in the National Center for Biotechnology Information database. PD-L1 is a ligand for programmed death 1 (PD-1) which belongs to the CD28/CTLA4 subfamily. Although in vitro study indicated that the cross-linking of PD-1 by PD-L1 leads to down-regulation of T-cell responses, some studies have shown that T cells stimulated with low levels of anti-CD3 and immobilized PD-L1-Ig were activated, proliferation and production of IFN- γ GM-CSF and IL-10 from the T cells were enhanced. The role of PD-L1 is now debatable.Synonyms: B7 homolog 1, B7H1, PD-L1, PDCD1 ligand 1, PDCD1L1, PDCD1LG1, Programmed cell death 1 ligand 1, Programmed death ligand 1
-
基因ID
- 29126
-
NCBI登录号
- NP_054862
-
UniProt
- Q9NZQ7
-
途径
- Cancer Immune Checkpoints
抗原
-